Health

Voltage regulator producer Empower closed a $45m round featuring Samsung Catalyst Fund while Swisscom and Six-backed spend management software provider Yokoy raised $26m.

The gastrointestinal disorder drug developer was co-founded by researchers from Stanford University.

The PPD-backed clinical trial software provider increased its overall funding to $521m in a series D round valuing it at $2.1bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The DNA printing technology received backing from investors including Merck Group, Illumina, Danaher and Agilent to hike its total funding to $280m.

Eli Lilly, MRL Ventures Fund and Leaps by Bayer were among the participants in a round disclosed as the gastrointestinal disorder drug developer launched.

The TigerMed-backed clinical research provider reportedly secured near to $100m in a round co-led by Sequoia Capital China and GL Ventures.

The cancer therapeutics developer has followed up an Eli Lilly-backed first close with an extra $25m, taking the round to $82.6m.

Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.

The digital therapeutics developer closed a series B round that included corporate venturing units and existing investors Hikma Ventures and Sanofi Ventures.

Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the immunotherapy developer.